secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001171843-26-001119
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst reports record FY2025 operating profit; ORLADEYO rev $601.8M (+38%); maintains FY2026 guidance
--------------------------------------------------------------------------------

- Full year 2025 GAAP operating profit $341.0M vs loss of $2.5M in 2024; total revenues $874.8M (incl $243.3M European sale) vs $450.7M.
- Non-GAAP total revenues $592.9M (+45% YoY); non-GAAP operating profit $214.2M (+198%).
- ORLADEYO net revenue $601.8M (+38% YoY; +43% ex-EU); FY2026 revenue guidance maintained at $625-645M.
- Completed acquisition of Astria Therapeutics (navenibart); FDA approved ORLADEYO oral pellets for pediatric HAE.
- Cash $337.5M at year-end; net cash generation $85.2M ex-debt payoff and EU sale proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/0001171843-26-001119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/f8k_022626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer